CN109350694B - 一种具有保健功效中药“全组分”提取物、其制备方法及应用 - Google Patents
一种具有保健功效中药“全组分”提取物、其制备方法及应用 Download PDFInfo
- Publication number
- CN109350694B CN109350694B CN201811029369.XA CN201811029369A CN109350694B CN 109350694 B CN109350694 B CN 109350694B CN 201811029369 A CN201811029369 A CN 201811029369A CN 109350694 B CN109350694 B CN 109350694B
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- soaking
- chinese medicine
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 108
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 230000000694 effects Effects 0.000 title abstract description 40
- 235000013402 health food Nutrition 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 130
- 238000002791 soaking Methods 0.000 claims description 64
- 239000000463 material Substances 0.000 claims description 60
- 239000000843 powder Substances 0.000 claims description 59
- 235000006533 astragalus Nutrition 0.000 claims description 55
- 238000001914 filtration Methods 0.000 claims description 34
- 238000001816 cooling Methods 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000469 ethanolic extract Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 18
- 239000008213 purified water Substances 0.000 claims description 18
- 241001061264 Astragalus Species 0.000 claims description 16
- 238000004108 freeze drying Methods 0.000 claims description 16
- 210000004233 talus Anatomy 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000036039 immunity Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000012669 liquid formulation Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 22
- 230000036541 health Effects 0.000 abstract description 12
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 55
- 241000045403 Astragalus propinquus Species 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 24
- 238000000034 method Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000006286 aqueous extract Substances 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 244000131316 Panax pseudoginseng Species 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 244000197580 Poria cocos Species 0.000 description 6
- 235000008599 Poria cocos Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 235000008434 ginseng Nutrition 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229940027941 immunoglobulin g Drugs 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000007126 Codonopsis pilosula Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940107666 astragalus root Drugs 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 241000180649 Panax notoginseng Species 0.000 description 4
- 235000003143 Panax notoginseng Nutrition 0.000 description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 244000248557 Ophiopogon japonicus Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 150000002212 flavone derivatives Chemical class 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 239000013585 weight reducing agent Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 241000382455 Angelica sinensis Species 0.000 description 2
- 241000305491 Gastrodia elata Species 0.000 description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940108605 cyclophosphamide injection Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- HKQYGTCOTHHOMP-UHFFFAOYSA-N formononetin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O HKQYGTCOTHHOMP-UHFFFAOYSA-N 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000305492 Gastrodia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- -1 calycosin glycoside Chemical class 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- RIKPNWPEMPODJD-UHFFFAOYSA-N formononetin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC=C2C1=O RIKPNWPEMPODJD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000036658 level of immunoglobulin M Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种具有保健功效的中药“全组分”提取物,其组成包括中药中水溶性和醇溶性等成分。本发明还提供所述中药“全组分”提取物制备方法及其及其保健用途。本发明提供的中药“全组分”提取物保留了中药的有效成分及功效的完整性,天然绿色、健康安全;可作为制备药品及健康食品的制剂原料,具有广泛的应用价值。
Description
技术领域:
本发明涉及一种中药“全组分”提取物,具体地说是一种具有保健功效的中药“全组分”提取物及由该提取物制备得到的药品及健康食品。
背景技术:
在生活节奏日益加快,生活压力越来越大的今天,“亚健康”状态愈来愈普遍。通过服用健康食品来提高自身免疫能力、改善身体机能成为大多数人的选者。以中药材及其提取物为原料的健康食品因为其功效明显、副作用低而颇受消费者青睐。发展以中药及中药提取物为基础的新型健康食品具有巨大的开发空间和社会、经济效益。
中医药作为中国文化的瑰宝,在中国已得到了上千年的发展、应用和临床验证。中药作为中医药的载体,其应用历史悠久。而具有保健功效的药食两用药材,其使用的安全性及保健功效得到了普遍的临床验证和认可。以该类药材的单味或者复方为原料的健康食品和营养补充剂,在亚洲、欧洲和美国等多地流行。
化学研究表明,中药含有的成分主要包括水溶性成份和醇溶性成分两大类。其二者在中药的有效性中均发挥重要的作用。目前市售中药保健相关产品多是以其水提物(富含多糖类等水溶性成分)为原料制备成的不同产品(包括颗粒剂、口服液、片剂等)。但是,水提取物中脂溶性小分子成分(皂苷类、黄酮类等)含量较低,因而这类产品在功效上只片面地代表了中药的部分药理活性。近年来,采用超微粉碎化技术的到了微粉药材,得到了广大消费者的青睐。虽然微粉药材在一定程度上保留了药材有效成分的完整性,改善了有效成分的溶出和吸收,但较大的服用量依然制约了其临床使用的依从性。此外,药材原粉贮存、流通过程中的易污染性,以及直接服用药材粉末对胃肠道粘膜的潜在刺激性,也使其安全性备受质疑。因此,在保证依从性和安全性的前提下,发展一种能尽可能保留中药活性成分完整性的提取物,将极大地推动其相关产品的进一步开发,具有广阔的市场前景和经济效益。
发明内容:
本发明的目的在于提供一种中药“全组分”提取物。
本发明的再一目的在于提供一种上述中药“全组分”提取物的制备方法。
本发明的第三目的在于提供利用上述中药“全组分”提取物制备的具有保健功效的药品及健康食品。
本发明中药“全组分”提取物以传统药食两用类中药为原料。
在发明中,重量份是指任何重量单位,例如克(g)、公斤(kg)等。
本发明提供一种具有保健功效的中药“全组分”提取物,该提取物由药食两用提取得到。
本发明提供一种具有保健功效的中药“全组分”提取物,所述提取物由药食两用经梯度溶剂提取法制备得到。
本发明提供所述中药“全组分”提取物或者所述提取物在制备具有保健功效的药品及健康食品中的应用。
在某些实施方案中,本发明所述药品及健康食品的形态包括固体制剂、液体制剂或半固体制剂。
本发明提供一种具有保健功效的中药制剂新原料,其包含本发明的中药“全组分”提取物或者本发明的中药“全组分”提取物以及制剂领域可接受的辅料。
一种制备中药“全组分”提取物的方法,其包括:
(1)取中药药材,低温干燥后粉碎;
(2)将中药药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥得到中药“全组分”提取物粉末。
所述的中药药材为黄芪、人参、天麻、麦冬、三七、丹参、党参、当归、陈皮、茯苓或山药。
在本发明方法中,所述步骤(5)的中药“全组分”提取液,需经溶剂梯度提取得到。
在本发明方法中,所述步骤(6)中中药“全组分”提取物粉末,为步骤(5)的中药“全组分”浓缩液经冷冻干燥得到提取物粉末。
本发明方法制备得到的中药“全组分”提取物可在制备具有保健功效的药品及健康食品中应用。
在本发明的保健功效用途,所述药物制剂及健康食品包括固体制剂、液体制剂或半固体制剂。
本发明提供一种具有保健功效的中药制剂原料,其包含本发明方法制备得到的中药“全组分”提取物和药物制剂及健康食品领域可接受的辅料。
有益效果
本发明提供中药材经提取、纯化得到的“全组分”提取物具有很好的保健功效。本发明通过考察不同制备方法对黄芪提取效率及主要成分含量影响,结果显示,采用不同的提取方法提取100g黄芪药材,其提取物总量依次为实施例1>对比例1>对比例2>对比例3。此外,无论是提取得到的总多糖、总皂苷以及主要黄酮的提取量,均以实施例1所得到的“全组分”提取物为最多。说明采用实施例1的梯度溶剂提取法,得到的“全组分”提取物中不同类别成分在提取效率上更高,且成分的完整性与分布特点与原药材更趋于一致,更能代表药材自身的特点。特别指出本发明获得全组分中药材,优于超微粉,无论是总提取物、总黄酮、多糖或皂苷。
此外,本发明主要针对于含有黄酮或皂苷的中药材,特别对黄芪做了全面考察,通过对提供黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠生长体重变化的影响,对小鼠各组小鼠的外周血白细胞数量的影响(1-19天),小鼠免疫器官的脏器指数的影响,对小鼠自然杀伤(NK)细胞的活性的影响,对小鼠血清中免疫球蛋白G(IgG)水平和免疫球蛋白M(IgM)水平的影响,结果显示“全组分”提取物效果为最佳。
整个过程制备方法简便,利用其制备得到的药物制剂及健康食品,本发明产品安全可靠,功效显著,易吸收。药食两用中药“全组分”提取物本身具有增强免疫力、缓解体力疲劳、抗氧化、延缓衰老等功效,故可将其作为功效性植物提取物添加剂添加到药物制剂及健康食品中,尤其是在制备具有增强免疫力及缓解体力疲劳等功效的药物制剂及健康食品中,具有广泛应用。
附图说明
图1.口服给予相同生药当量(1g生药/kg/天)的本发明提供黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠生长体重变化的影响。##p<0.01相对于正常对照组有极显著性差异;**p<0.01相对于模型对照组有极显著性差异。
图2.口服给予相同生药当量(1g生药/kg/天)的本发明提供的黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠各组小鼠的外周血白细胞数量的影响(1-19天)A和第19天对小鼠各组小鼠的外周血白细胞数量的影响B。###p<0.001相对于正常对照组有极显著性差异;**p<0.01相对于模型对照组有极显著性差异。
图3.口服给予相同生药当量(1g生药/kg/天)的本发明提供的黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠免疫器官的脏器指数的影响,其中A为脾脏,B为胸腺。###p<0.001相对于正常对照组有极显著性差异;**p<0.01,***p<0.001相对于模型对照组有极显著性差异。
图4.口服给予相同生药当量(1g生药/kg/天)的本发明提供的黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠脾淋巴细胞增殖能力的影响。#p<0.05相对于正常对照组有显著性差异,###p<0.001相对于正常对照组有极显著性差异;**p<0.01,***p<0.001相对于模型对照组有极显著性差异。
图5.口服给予相同生药当量(1g生药/kg/天)的本发明提供的黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠自然杀伤(NK)细胞的活性的影响。##p<0.01相对于正常对照组有极显著性差异;**p<0.01,***p<0.001相对于模型对照组有极显著性差异。
图6.口服给予相同生药当量(1g生药/kg/天)的本发明提供的黄芪“全组分”提取物(WCE)、黄芪药材微粉(CBP)或黄芪水提物(WAE)对小鼠血清中免疫球蛋白G(IgG)水平A和免疫球蛋白M(IgM)水平B的影响。###p<0.001相对于正常对照组有极显著性差异;*p<0.05相对于模型对照组有显著性差异,**p<0.01,***p<0.001相对于模型对照组有极显著性差异。
具体实施方式
本实施例所用黄芪药材及微粉药材均从贵州广济堂药业有限公司购买得到,质量符合中华人民共和国药典2015年版标准及广东省中药破壁饮片质量标准研究规范。
本实施例所用人参、天麻、麦冬、三七、丹参、党参、当归、陈皮、茯苓、山药等药材均从成都荷花池药材批发市场购买得到,质量符合中华人民共和国药典2015年版标准。
实施例1本发明黄芪“全组分”提取物的制备
(1)取黄芪药材,低温干燥后粉碎;
(2)将黄芪药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明黄芪“全组分”提取物粉末。
对比例1本发明黄芪水提取物的制备
(1)称取取黄芪药材粉末;
(2)加入10倍药材重量体积的纯化水,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至适当体积;
(6)浓缩液经冷冻干燥,得到本发明黄芪水提取物粉末。
对比例2本发明黄芪50%乙醇提取物的制备
(1)称取取黄芪药材粉末;
(2)加入10倍药材重量体积的50%乙醇,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明黄芪50%乙醇提取物粉末。
对比例3本发明黄芪95%乙醇提取物的制备
(1)称取取黄芪药材粉末;
(2)加入10倍药材重量体积的95%乙醇,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的95%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集提取液,药渣再加入10倍药材重量体积的95%乙醇,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明黄芪95%乙醇提取物粉末。
实施例2黄芪不同制备方法提取物收率及主要成分含量的比较按照上述实施例1及对比例1-3的方法分别制备黄芪“全组分”提取物、水提取物、50%乙醇提取物以及95%乙醇提取物。
(1)记录提取物经冷冻干燥后得到的粉末的重量,按下列公式计算提取效率:
提取效率(%)=提取物粉末的重量/药材的重量×100%
(2)采用浓硫酸-苯酚法,测定不同制备方法得到提取物粉末中总多糖的含量。
(3)采用香草醛-冰醋酸法,测定不同制备方法得到提取物粉末中总皂苷的含量。
(4)采用UPLC-UV法,测定不同制备方法得到提取物粉末中4种主要黄酮(芒柄花素、芒柄花苷、毛蕊异黄酮和毛蕊异黄酮苷)的总含量。
不同制备方法对黄芪提取效率及主要成分含量影响的结果见表1。采用不同的提取方法提取100g黄芪药材,其提取物总量依次为实施例1>对比例1>对比例2>对比例3。此外,无论是提取得到的总多糖、总皂苷以及主要黄酮的提取量,均以实施例1所得到的“全组分”提取物为最多。说明采用实施例1的梯度溶剂提取法,得到的“全组分”提取物中不同类别成分在提取效率上更高,且成分的完整性与分布特点与原药材更趋于一致,更能代表药材自身的特点。
表1:不同制备方法对提取物收率及主要成分含量的影响。括号中数值表示根据具体实施例的提取方法,每100(g)药材提取得到相应成分的总量(g)
实施例 | 对比例1 | 对比例2 | 对比例3 | 实施例1 |
提取溶剂 | 纯化水 | 50%乙醇 | 95%乙醇 | 梯度提取 |
提取物总量(g) | 30.43 | 24.33 | 8.70 | 31.27 |
提取物中总多糖总量(g) | 11.52 | 8.05 | 2.52 | 12.87 |
提取物中总皂苷总量(g) | 0.25 | 0.23 | 0.16 | 0.52 |
提取物中4种黄酮总量(g) | 0.029 | 0.056 | 0.044 | 0.065 |
实施例3黄芪不同提取物及药材微粉调节小鼠免疫功能的功效比较黄芪水提物及微粉药材为当前市售黄芪相关产品的主要原料。在此比较了黄芪水提物(对比例1制备得到)、黄芪药材微粉(贵州广济堂药业有限公司购买得到)以及黄芪“全组分”提取物(实施例1制备得到)调解小鼠免疫功能的功效。
实验采用的ICR小鼠(雌雄各半,7周龄,体重18-24g)购于澳门大学健康科学学院动物中心,饲养于温度22±1℃,湿度50-60%的洁净环境。所有动物实验操作均经过澳门大学动物伦理委员会审核批准。
小鼠随机分为5组(每组6只),包括正常对照组(A)、模型对照组(B)、“全组分”提取物(C)、水提取物组(D)和药材微粉组(E)。其中(A)、(B)组口服给予纯化水,(C)、(D)和(E)组分别口服给予相同生药当量(1g生药/kg/天)的黄芪“全组分”提取物(实施例4)、黄芪药材微粉(贵州广济堂药业有限公司)或黄芪水提物(实施例1)的水分散液。每天灌胃两次,连续给药18天。在给药第12-14天,(B)~(E)组小鼠每天腹腔注射环磷酰胺溶液(80mg/kg/d),(A)组小鼠每天腹腔注射相同体积的生理盐水。在最后一次环磷酰胺注射后的第五天,颈椎脱臼处死小鼠。实验过程中,进行以下免疫相关指标的测定和比较。
(1)小鼠体重的变化
在整个实验过程中,记录小鼠体重的变化,观察其生长状态。结果见附图1。在注射环磷酰胺造模前,各组小鼠生长的体重变化无明显差异,说明服用量下黄芪的安全性。造模后,各组动物的体重相对于正常对照组均有下降,而各给药组均改善腹腔注射环磷酰胺引起的体重下降,其效果依次为“全组分”提取物>药材微粉>水提取物。
(2)外周血白细胞数量
于实验的第1、7、12、14和19天,分别从小鼠尾静脉吸取新鲜血液10μL,加入20倍体积的3%冰醋酸溶液稀释裂解红细胞,再吸取10μl至血细胞计数板,于显微镜下计数外周血白细胞数量。结果见附图2。造模前,口服黄芪对小鼠外周血白细胞数量无显著影响;造模后,各组小鼠外周血白细胞数量显著下降,但服用黄芪药材微粉及各种提取物均能改善外周血白细胞数量下降的程度,且以“全组分”提取物效果为最佳。
(3)免疫器官的脏器指数
小鼠处死后,于无菌条件下收集主要免疫器官(包括脾脏和胸腺),称重,按下列公式计算脏器指数:
脏器指数(mg/g)=脾脏或者胸腺的重量/体重。
结果见附图3。相对于模型对照组,各给药组均能一定程度减少腹腔注射环磷酰胺引起的免疫器官重量下降,提高其脏器指数,且以“全组分”提取物效果为最佳。
(4)脾淋巴细胞增殖能力
小鼠脾脏经消解后,100μm滤网无菌过滤,获得单细胞悬液。加入ACK裂解液裂解红细胞,于4℃下400×g速度离心,收集脾淋巴细胞,用PBS洗涤三次后分散于RPMI1640培养液,台盼蓝染色后计数活细胞达到95%以上。
[1]取上述脾淋巴细胞悬浮液,以5×105细胞/孔的密度接种于96孔板上,加入刀豆蛋白A(ConA,终浓度为5μg/mL)或脂多糖(LPS,终浓度为10μg/mL),于培养箱中(37℃,5%CO2)共培养72小时后,每孔加入10μL的CCK-8溶液,继续培养1小时,在酶联免疫检测仪上测定吸光度,测定波长450nm,参考波长650nm。按下列公式计算计算脾淋巴细胞增值率:
脾淋巴细胞增殖率(%)=测试组吸光度/正常对照组×100(%)
结果见附图4。相对于模型对照组,各给药组均在一定程度上提高脾淋巴细胞的增殖能力,且以“全组分”提取物效果为最佳。
(5)自然杀伤(NK)细胞活性
将100μLYac-1细胞靶细胞(4×105个/mL)与100μL脾细胞效应细胞(2×107个/mL)按效靶比50:1的条件接种于96板,于培养箱中(37℃,5%CO2)共培养4小时后,离心。吸取100μL上清液,加入乳酸脱氢酶(LDH)反应试剂后,测定吸光度。以无血清的RPMI1640培养基作为空白对照组,含1%NP-40的培养基为最大释放组,按下列公式NK细胞活性:
NK细胞活性(%)=(A实验组-A空白对照组)/(A最大释放组-A空白对照组)×100(%)
结果见附图5。相对于模型对照组,各给药组均在一定程度上提高自然杀伤(NK)细胞的活性,且以“全组分”提取物效果为最佳。
(6)血清免疫球蛋白水平
于实验最后一天收集小鼠血清,采用血清免疫球蛋白测定试剂盒(购买自南京建成生物工程研究所),测定血清中免疫球蛋白G(IgG)和免疫球蛋白M(IgM)的水平。结果见附图6。相对于模型对照组,各给药组均能有效提高血清IgG和IgM的水平,且以“全组分”提取物效果为最佳。
实施例4本发明人参“全组分”提取物的制备
(1)取人参药材,低温干燥后粉碎;
(2)将人参药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明人参“全组分”提取物粉末。
实施例5本发明天麻“全组分”提取物的制备
(1)取天麻药材,低温干燥后粉碎;
(2)将天麻药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明天麻“全组分”提取物粉末。
实施例6本发明麦冬“全组分”提取物的制备
(1)取麦冬药材,低温干燥后粉碎;
(2)将党参药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明麦冬“全组分”提取物粉末。
实施例7本发明三七“全组分”提取物的制备
(1)取三七药材,低温干燥后粉碎;
(2)将三七药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明三七“全组分”提取物粉末。
实施例8本发明丹参“全组分”提取物的制备
(1)取丹参药材,低温干燥后粉碎;
(2)将丹参药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明丹参“全组分”提取物粉末。
实施例9本发明党参“全组分”提取物的制备
(1)取党参药材,低温干燥后粉碎;
(2)将党参药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明党参“全组分”提取物粉末。
实施例10本发明当归“全组分”提取物的制备
(1)取当归药材,低温干燥后粉碎;
(2)将当归药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明当归“全组分”提取物粉末。
实施例11本发明陈皮“全组分”提取物的制备
(1)取陈皮药材,低温干燥后粉碎;
(2)将陈皮药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明陈皮“全组分”提取物粉末。
实施例12本发明茯苓“全组分”提取物的制备
(1)取茯苓药材,低温干燥后粉碎;
(2)将茯苓药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明茯苓“全组分”提取物粉末。
实施例13本发明山药“全组分”提取物的制备
(1)取山药药材,低温干燥后粉碎;
(2)将山药药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3)冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4)冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5)冷却至室温后过滤。合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6)浓缩液经冷冻干燥,得到本发明山药“全组分”提取物粉末。
本发明提取物可以进一步制成(但不限于)以下剂型:
实施例14:黄芪颗粒
颗粒剂使用方便,质量可控,安全性高。将所得到的本发明黄芪“全组分”提取物用水溶解(药材:水≈3:1)制成浸膏,加入适量蔗糖粉、糊精(浸膏:蔗糖:糊精=1:3:1)及用适量乙醇制软材,挤压过筛(12-16目)制颗粒,60℃鼓风干燥,整粒,烘干,分装即得。使制得得颗粒不能通过一号筛和能通过五号筛的总和不得超过15%。
实施例15:黄芪泡腾片
泡腾片携带方便,起效迅速,生物利用度高。将所得到的本发明黄芪“全组分”提取物用水溶解(药材:水≈3:1)制成浸膏,按照浸膏:糊精=1.7:1的比例加入糊精,搅匀,真空干燥,粉碎后按照干粉:泡腾剂(枸橼酸与碳酸氢钠1:1)1.3:1混合后,加入CMC-Na 4%,用95%乙醇制粒,干燥,外加预胶化淀粉6%,阿斯帕坦和硬脂酸镁适量,混合均匀后压片即得。整个压片过程环境湿度需在45%以内。
Claims (4)
1.一种具有增加免疫功效的中药“全组分”提取物,其特征在于,提取物包含中药中水溶性和醇溶性成分;所述的提取物由如下步骤实现制备获得:
(1) 取中药药材,低温干燥后粉碎;
(2) 将中药药材粉末用10倍药材重量体积的95%乙醇浸泡,浸泡时间为1小时,60℃浸泡提取1小时;
(3) 冷却至室温后过滤,收集95%乙醇提取液,药渣再加入10倍药材重量体积的50%乙醇,60℃浸泡提取1小时;
(4) 冷却至室温后过滤,收集50%乙醇提取液,药渣再加入10倍药材重量体积的纯化水,60℃浸泡提取1小时;
(5) 冷却至室温后过滤;
合并三次提取液,减压浓缩至完全去除乙醇后再浓缩至适当的体积;
(6) 浓缩液经冷冻干燥得到中药“全组分”提取物粉末;
所述中药材为黄芪。
2.如权利要求1所述的提取物在制备增加免疫的药品及健康食品制剂中的应用。
3.如权利要求2所述的应用,其特征在于,所述药品及健康食品制剂为固体制剂、液体制剂或半固体制剂。
4.如权利要求3所述的应用,其特征在于所述的药品及健康食品制剂还含有药品领域可接受的辅料及健康食品领域可接受的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811029369.XA CN109350694B (zh) | 2018-09-05 | 2018-09-05 | 一种具有保健功效中药“全组分”提取物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811029369.XA CN109350694B (zh) | 2018-09-05 | 2018-09-05 | 一种具有保健功效中药“全组分”提取物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109350694A CN109350694A (zh) | 2019-02-19 |
CN109350694B true CN109350694B (zh) | 2021-11-16 |
Family
ID=65350253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811029369.XA Active CN109350694B (zh) | 2018-09-05 | 2018-09-05 | 一种具有保健功效中药“全组分”提取物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109350694B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723999A (zh) * | 2005-04-08 | 2006-01-25 | 周宜轩 | 治疗冠心病心绞痛的药物组合物的制剂处方及制备方法 |
-
2018
- 2018-09-05 CN CN201811029369.XA patent/CN109350694B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723999A (zh) * | 2005-04-08 | 2006-01-25 | 周宜轩 | 治疗冠心病心绞痛的药物组合物的制剂处方及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109350694A (zh) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
CN103285231B (zh) | 一种用于糖尿病辅助治疗的药物组合物及其制法 | |
TWI733980B (zh) | 一種具有增強免疫力功能的粉劑及其製備方法 | |
CN108014150A (zh) | 天然药物组合物在制备抗缺氧和抗辐射的药物或食品中的应用 | |
CN103191298B (zh) | 一种治疗母婴血型不合的中药组合物及其制备方法 | |
CN109091530B (zh) | 紫苏叶提取物在预防或治疗再生障碍性贫血中的应用 | |
CN113069510A (zh) | 一种增强免疫力的组合物及其制备方法和应用 | |
CN110664883B (zh) | 一种具有生精作用的药物组合物 | |
CN106421208B (zh) | 一种具有抗化学性肝损伤功能的药物组合物及其制备方法 | |
CN107912771A (zh) | 一种具有增强免疫功能的石斛组合物及其制备方法 | |
CN109350694B (zh) | 一种具有保健功效中药“全组分”提取物、其制备方法及应用 | |
CN105796625A (zh) | 含红曲红花的药物组合物及其制剂 | |
CN110755601B (zh) | 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用 | |
CN104225472A (zh) | 一种治疗口腔粘膜病变的中药制剂及制备方法和用途 | |
RU2642256C2 (ru) | Применение композиции в получении медицинской продукции или лекарственного средства для профилактики и лечения вызванной лучевой и химиотерапией лейкопении | |
CN101024060B (zh) | 金嗓散结制剂的制备方法 | |
CN104688723B (zh) | 淫羊藿苷元在制备治疗贫血药物中的应用 | |
CN107373664B (zh) | 一种具有抗pm2.5颗粒物功效的组合物 | |
CN110663948A (zh) | 一种具有增强免疫力作用的保健品及其制备方法 | |
CN101357212B (zh) | 一种复方斑蝥注射制剂及其制备方法 | |
CN101011543A (zh) | 一种新的抗肿瘤药物组合物 | |
CN115501293B (zh) | 熟地黄山药葛根降糖组合物的制备方法 | |
CN106334018B (zh) | 一种治疗肝细胞性肝癌的中药组合物及其应用 | |
CN105250919B (zh) | 一种用于预防和/或治疗肝疾病的中药组合物及其制备方法 | |
CN1970034B (zh) | 一种中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |